use
porcin
islet
replac
insulinproduc
islet
destroy
diabetogen
diseas
process
present
distinct
challeng
option
becom
therapeut
realiti
treatment
type
diabet
challeng
includ
thorough
evalu
microbiolog
safeti
islet
studi
describ
robust
porcin
isletscreen
program
provid
high
level
confid
microbiolog
safeti
porcin
islet
suitabl
clinic
trial
ultim
goal
treatment
type
diabet
restor
physiolog
blood
glucos
regul
without
requir
lifelong
therapi
immunosuppress
immunoregul
numer
challeng
attain
goal
divers
approach
rang
insulin
pump
gene
therapi
stem
cell
strategi
pursu
anoth
approach
replac
lost
islet
cell
human
islet
allotransplant
establish
clinic
util
islet
graft
although
human
islet
recipi
remain
insulinindepend
year
major
patient
retain
graft
function
evidenc
persist
cpeptid
secret
importantli
islet
transplant
larg
elimin
hypoglycem
unawar
postgraft
improv
longterm
insulin
independ
like
data
select
method
fourcheckpoint
program
systemat
screen
donor
herd
larg
white
yorkshir
landrac
hybrid
anim
individu
sentinel
pancrea
donor
anim
critic
islet
macrobead
molecular
assay
screen
known
virus
electron
microscopi
vitro
studi
employ
screen
potenti
new
diverg
emerg
virus
organ
institut
indic
increas
number
islet
recipi
approach
abl
maintain
extern
insulin
independ
year
nonetheless
avail
suitabl
human
pancreas
either
whole
organ
isol
islet
transplant
entir
inadequ
evidenc
recoveri
donor
pancreas
unit
state
use
xenogen
islet
could
provid
solut
limit
suppli
human
islet
transplant
porcin
islet
particularli
suitabl
sourc
insulinproduc
cell
porcin
insulin
differ
human
insulin
singl
amino
acid
porcin
insulin
shown
provid
reliabl
safe
glycem
control
human
diabet
patient
furthermor
transplant
whole
pancrea
intact
islet
langerhan
expect
replic
normal
precis
physiolog
glucos
control
depend
varieti
cell
type
protein
pancreat
islet
enorm
complex
regulatori
machineri
absent
approach
reestablish
normoglycemia
use
animalderiv
islet
tissu
howev
necessit
either
suppress
patient
immun
system
physic
isol
islet
prevent
reject
previous
describ
abil
agaroseagaros
encapsul
porcin
islet
function
diabet
anim
model
encapsul
islet
macrobead
least
partial
immun
isol
outer
layer
dens
agaros
prohibit
direct
cell
access
xenogen
islet
although
small
immun
mediat
cytokin
still
enter
macrobead
encapsul
approach
suffici
robust
allow
spontan
diabet
bb
rat
surviv
month
without
immunosuppress
without
exogen
insulin
administr
ongo
studi
nonimmunosuppress
diabet
cynomolgu
macaqu
also
demonstr
porcin
islet
macrobead
function
month
anim
unpublish
data
see
checkpoint
clinic
use
islet
anim
also
requir
wellthoughtout
strategi
assur
microbiolog
safeti
anim
tissu
strategi
provid
asept
product
reduc
probabl
inadvert
transmiss
adventiti
virus
critic
success
implement
excit
therapi
approach
take
advantag
uniqu
aspect
islet
macrobead
name
longterm
viabil
cultur
lack
patient
immunosuppress
limit
microbiolog
safeti
risk
porcin
islet
transplant
essenti
approach
establish
four
checkpoint
span
macrobead
product
transplant
process
checkpoint
approach
built
upon
increas
level
microbiolog
screen
donor
herd
islet
product
use
multipl
assay
format
abil
screen
known
unknown
pathogen
use
checkpoint
approach
provid
evid
support
use
donor
anim
hous
high
hygien
hepafilt
environ
islet
xenotransplant
also
xenocel
therapi
studi
present
document
effect
microbiolog
safeti
strategi
minim
microbiolog
risk
agaros
encapsul
porcin
islet
treatment
type
diabet
donor
pig
larg
white
yorkshir
landrac
hybrid
anim
obtain
wellcharacter
nongenet
modifi
choic
genet
formerli
newsham
sourc
anim
sourc
anim
facil
independ
own
herd
locat
rural
southwest
ohio
breed
herd
number
approxim
sow
util
twotier
quarantin
test
system
modern
multisit
product
strategi
three
segreg
facil
nurseri
gilt
isol
farrow
gestat
maintain
data
record
follow
standard
oper
procedur
sop
anim
husbandri
vaccin
hous
clean
wast
manag
biosecur
measur
control
transport
anim
suppli
semen
feed
water
pest
rodent
control
gravel
barrier
around
facil
perimet
caretak
qualif
includ
routin
health
assess
compon
comprehens
biosecur
program
routin
qualiti
assur
site
audit
use
verifi
complianc
cornbas
pig
feed
produc
exclus
corn
grown
ground
onsit
sourc
anim
facil
gilt
gestat
sow
lactat
sow
given
base
feed
consist
corn
variou
supplement
eg
amino
acid
vitamin
miner
protein
slight
variat
base
breed
statu
anim
ingredi
use
product
complet
feed
certifi
free
restrict
use
protein
product
de
facil
hold
pork
qualiti
assur
plu
pqa
plu
certif
producerdriven
program
ensur
us
pork
product
highest
qualiti
safe
pqa
plu
program
mandat
good
product
practic
emphasi
biosecur
practic
reduc
risk
introduc
spread
infecti
agent
retir
breed
sow
use
pancrea
donor
sent
local
abattoir
pork
product
sourc
anim
routin
vaccin
variou
agent
quarterli
sentinel
follow
electr
stun
exsanguin
usdaregul
abattoir
complianc
feder
regul
concern
anim
handl
welfar
numer
tissu
includ
brain
heart
lung
liver
tonsil
lymph
node
spleen
ileum
kidney
pancrea
bone
marrow
pbmc
fece
serum
collect
archiv
fix
frozen
aliquot
time
pancrea
procur
aliquot
isol
islet
also
frozen
archiv
donor
anim
tissu
sampl
sent
univers
minnesota
veterinari
diagnost
laboratori
mvdl
screen
bacteri
viral
pathogen
list
tabl
mvdl
one
three
major
swine
diagnost
laboratori
donor
pancreas
procur
sow
year
age
histori
multipl
pariti
follow
electr
stun
exsanguin
donor
abdomin
viscera
retriev
sterilegown
technician
transfer
steril
contain
transport
viscera
place
custom
built
hepafilt
laminar
flow
work
station
tissu
retriev
surfac
monitor
perform
work
surfac
prior
retriev
settl
plate
place
insid
workstat
dissect
monitor
microbiolog
contamin
intact
pancrea
dissect
viscera
sterilegown
technician
immedi
provid
absolut
viral
sequestr
although
encapsul
islet
protect
direct
immun
cell
contact
agaras
enzym
necessari
break
agaros
abund
oceandwel
bacteria
found
mammal
macrobead
absenc
trauma
remain
intact
indefinit
follow
implant
abdomin
caviti
macrobead
cultur
humidifi
atmospher
co
collect
microbiolog
screen
implanta
colon
ileum
liver
spleen
lung
mesenter
lymph
node
b
coronaviru
n
caudoviral
n
c
small
round
viral
particl
dilut
factor
df
e
kidney
lung
mesenter
lymph
node
tonsil
spleen
f
test
perform
nation
veterinari
servic
laboratori
g
bacteriophag
h
df
n
n
n
n
n
n
j
df
n
n
n
k
df
n
n
l
df
n
n
df
n
n
n
n
heart
intestin
liver
pancrea
kidney
lung
mesenter
lymph
node
tonsil
spleen
ny
usa
prescreen
endotoxin
euml
steril
contain
mmoll
glucos
heatinactiv
porcin
serum
biologo
montgomeri
il
usa
prescreen
steril
absenc
mycoplasma
adventiti
virus
per
endotoxin
euml
antibioticantimycot
life
technolog
chang
weekli
postchang
media
sampl
taken
porcin
insulin
elisa
assay
mercodia
uppsala
sweden
islet
isol
encapsul
procedur
perform
class
ii
biosafeti
cabinet
within
iso
class
rest
iso
class
activ
process
laboratori
sterilegown
technician
routin
environment
monitor
includ
particl
count
viabl
particl
count
settl
plate
surfac
monitor
perform
everi
islet
isol
procedur
macrobead
given
donor
assign
uniqu
islet
isol
number
cultur
separ
islet
macrobead
produc
donor
anim
prior
islet
macrobead
implant
repres
sampl
macrobead
sent
steril
test
per
usp
six
nonimmunosuppress
streptozotocininduc
diabet
male
cynomolgu
macaqu
mauritian
asian
origin
median
age
multipl
checkpoint
process
porcin
islet
isol
encapsul
cultur
transplant
implement
assess
microbiolog
safeti
islet
macrobead
figur
step
test
sampl
spike
intern
extract
control
iec
plant
rna
dna
detect
limit
mimick
target
nucleic
acid
process
allow
level
nucleic
acid
recoveri
presenc
test
sampl
assess
ensur
low
level
rna
dna
recov
given
evid
satisfactori
insulin
product
cultur
islet
macrobead
macrobead
sent
viral
screen
sg
vitrolog
prior
use
preclin
anim
studi
islet
macrobead
neg
virus
screen
pcr
n
virus
cocultur
assay
use
four
differ
suscept
cell
line
n
pancrea
donor
anim
tabl
transmiss
scan
electron
microscopi
incorpor
tabl
figur
neg
bacteri
growth
presenc
endotoxin
mycoplasma
tabl
although
sourc
materi
product
releas
screen
recipi
monitor
postmacrobead
implant
provid
valuabl
data
could
use
treat
individu
patient
also
check
tabl
moreov
evid
viral
infect
observ
document
health
statu
anim
fourcheckpoint
microbiolog
safeti
program
outlin
util
four
separ
assess
microbiolog
safeti
agaros
focu
guidelin
includ
ixa
statement
safeti
xenotransplant
invit
review
us
xenogen
regul
publish
fda
staff
provid
addit
detail
fda
guidelin
schuurman
recent
publish
thorough
overview
worldwid
xenogen
regul
emphasi
european
requir
f
g
u
r
e
transmiss
electron
microscopi
islet
cell
profil
typic
present
sampl
cell
examin
islet
cell
gener
adher
intercellular
connect
cell
junction
desmosom
observ
cell
surfac
appear
vari
smooth
surfac
bleb
cell
process
observ
variou
cell
type
present
includ
cell
mitot
cell
observ
light
electron
microscopi
signific
number
dead
die
cell
present
popul
cell
examin
nuclear
profil
vari
size
cell
one
nuclear
profil
visibl
often
indent
invagin
contain
lacuna
cytoplasm
materi
nucleoli
promin
sometim
one
observ
heterochromatin
abund
clump
found
inner
nuclear
membran
sporad
throughout
nucleu
cell
normal
rang
organel
mitochondria
numer
vari
size
shape
presenc
crista
note
although
matrix
granul
seen
golgi
bodi
observ
promin
exhibit
stack
cisterna
roughsurfac
endoplasm
reticulum
extens
occur
vari
length
lipid
bodi
peroxisom
multivesicular
bodi
present
free
ribosom
polysom
fibril
found
throughout
cytoplasm
vacuol
electron
dens
floccul
materi
observ
coat
uncoat
secretori
vesicl
vari
type
seen
centriol
microtubul
present
cell
structur
consist
morpholog
expect
secretori
cell
virus
viruslik
particl
extran
agent
includ
mycoplasma
yeast
fungi
bacteria
found
abbrevi
f
fibril
mitochondria
desmosom
arrow
centriol
c
nucleu
nu
golgi
bodi
g
lipid
bodi
l
vacuol
v
multivesicular
bodi
mvb
roughsurfac
endoplasm
reticulum
rer
microbiolog
safeti
program
inlin
issu
consider
fda
xenotransplant
guidelin
well
ixa
statement
regard
donor
anim
import
note
guidelin
state
sourc
anim
must
rais
hepafilt
environ
signific
addit
difficulti
obtain
maintain
pathogenfre
swine
guarante
pancrea
individu
anim
suitabl
islet
isol
fact
becom
increas
clear
porcin
pancreas
yield
suffici
number
islet
clinic
use
given
limit
approach
rais
sourc
anim
high
hygien
environ
biopsi
individu
pancreas
islet
isol
suitabl
perform
extens
microbiolog
screen
select
donor
anim
tissu
islet
macrobead
methodolog
howev
employ
altern
approach
fdarecommend
quarantin
period
individu
donor
anim
deserv
discuss
minimum
quarantin
period
anim
use
process
biolog
product
also
state
cfr
part
rational
quarantin
period
provid
time
acut
infect
becom
clinic
appar
reliabl
peripher
blood
cell
thu
islet
macrobead
tissu
implant
undergo
quarantin
abil
thoroughli
screen
islet
use
wide
varieti
specif
nonspecif
assay
obviat
need
rais
quarantin
donor
anim
hepafilt
environ
discuss
time
point
evalu
month
day
month
day
posttranspl
addit
sampl
year
day
year
day
year
day
year
day
posttranspl
evalu
subset
recipi
reach
time
point
extend
followup
b
l
e
pcr
screen
implant
nonhuman
primat
treatment
option
case
suspect
pathogen
transmiss
also
manufactur
decis
well
feedback
checkpoint
may
result
modif
one
checkpoint
medic
procedur
alway
risk
transplant
porcin
islet
challeng
face
understand
risk
minim
accept
level
light
expect
clinic
benefit
potenti
risk
viral
transfer
transplant
cell
recipi
major
safeti
concern
address
issu
test
rational
develop
screen
sentinel
donor
anim
virus
present
herd
special
interest
known
zoonot
agent
known
infect
swine
usa
initi
character
perv
infect
statu
sourc
herd
perform
given
unlik
abil
least
time
elimin
endogen
retrovirus
grow
conclus
risk
perv
transmiss
human
xenotransplant
trial
particip
low
addit
cocultur
electron
microscopi
assay
employ
look
unknown
virus
would
prompt
effort
identifi
viru
either
known
unknown
agent
eg
prrsv
induc
cpe
cell
one
compon
islet
macrobead
screen
also
part
releas
criteria
islet
macrobead
confirm
steril
free
mycoplasma
signific
level
en
cultur
sequenc
found
purifi
islet
isol
absenc
porcin
serum
also
detect
sequenc
domest
intern
porcin
serum
sourc
phov
screen
islet
macrobead
cultur
sera
postpon
suitabl
phovfre
sourc
could
obtain
regard
perv
identif
viru
abil
cross
speci
barrier
princip
concern
porcin
xenotransplant
worth
mention
nhp
ideal
model
assess
risk
perv
transmiss
cynomolgu
monkey
lack
perva
receptor
major
receptor
perva
pervac
entri
actual
risk
perv
infect
clinic
remain
unclear
far
transmiss
perv
porcin
microorgan
human
expos
pig
islet
cell
consid
find
well
neg
viral
find
diabet
dog
expos
porcin
islet
macrobead
year
evid
viral
transmiss
follow
macrobead
implant
low
risk
studi
canin
cell
shown
cell
perva
receptor
appar
degre
human
cell
nonmicrobiolog
risk
patient
also
exist
must
consid
part
comprehens
safeti
evalu
includ
procedur
risk
accompani
preand
postimplant
screen
well
gener
anesthesia
laparoscop
surgeri
requir
implant
macrobead
procedur
risk
well
known
although
real
modest
implant
cancer
macrobead
encapsul
mous
renal
adenocarcinoma
cell
treat
patient
variou
malign
year
without
advers
event
attribut
macrobead
either
intraperiton
irrit
microbiolog
hazard
see
also
clinicaltrialsgov
identifi
final
import
consider
immun
statu
recipi
recent
progress
clinic
islet
allotransplant
confirm
potenti
islet
graft
reduc
exogen
insulin
administr
occurr
hypoglycem
unawar
result
encourag
numer
advers
event
includ
intrahepat
bleed
neutropenia
mouth
ulcer
anemia
diarrhea
edema
hypercholesterolemia
pharyng
report
report
advers
event
primarili
associ
immunosuppress
therapi
encapsul
porcin
islet
use
agaroseagaros
method
elimin
need
immunosuppress
therapi
fulli
compet
immun
system
expect
significantli
reduc
risk
xenozoonot
infect
last
year
understand
risk
associ
porcin
xenotransplant
methodolog
manag
risk
includ
theoret
risk
potenti
presenc
unknown
pathogen
significantli
progress
recent
ixa
consensu
updat
note
theoret
risk
still
exist
relat
transmiss
infecti
agent
employ
appropri
safeguard
event
like
rare
occur
although
actual
risk
islet
xenotransplant
known
absenc
clinic
trial
state
fishman
clinic
xenotransplant
level
safeti
develop
beyond
avail
human
